NGM Biopharmaceuticals Inc (NASDAQ:NGM)
| 5.38 Delayed Data As of Nov 25 |  +0.045 / +0.84%Today’s Change | 2.92 Today|||52-Week Range 19.14 | -69.65% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $436.4M |
Company Description
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
Contact Information
NGM Biopharmaceuticals, Inc. 333 Oyster Point Boulevard South San Francisco California 94080-7014 |
Employees
Shareholders
| Individual stakeholders | 33.99% |
| Other institutional | 26.12% |
| Mutual fund holders | 18.58% |
Top Executives
| David J. Woodhouse | Chief Executive Officer & Director |
| Siobhan Nolan Mangini | President & Chief Financial Officer |
| Jin Long Chen | Director & Chief Scientific Officer |
| Hui Tian | Vice President-Research |
| Marc Learned | Vice President-Research Operations |
